Pfizer announces a revised efficacy rating of 91.3% for its vaccine candidate, down from its original rating of 95%, and affirms that protection afforded by the vaccine lasts for at least six months. Pfizer also announces that the vaccine appeared to provide protection against the 501.V2 variant in 100% of cases during its South African trial run.